ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis

Carcinogenesis

Volumn 30, Issue 11, 2009, Pages 1841-1847

  O'Hayer, Kevin M ^a   Brady, Donita C ^a   Counter, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; INTERLEUKIN 6; INTERLEUKIN 8; MYC PROTEIN; RAS PROTEIN; SHORT HAIRPIN RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; MALE; MOUSE; NONHUMAN; ONCOGENE C H RAS; ONCOGENE RET; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINES, CXC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, INTERLEUKIN-8B; SKIN NEOPLASMS;

EID: 70849134402     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp198     Document Type: Article

References (41)

1. Bos,J.L. (1989) ras oncogenes in human cancer: A review. Cancer Res. 49, 4682-4689.
2. Downward,J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer, 3, 11-22.
3. Okada,F. et al. (1998) Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/ vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA, 95, 3609-3614.
4. Rak,J. et al. (2000) Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res., 60, 490-498.
5. Sparmann,A. et al. (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458.
6. Ahuja,S.K. et al. (1996) The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem., 271, 20545-20550.
7. Wigmore,S.J. et al. (2002) Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int. J. Oncol., 21, 881-886.
8. Tas,F. et al. (2006) Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest., 24, 492-496.
9. Brennecke,S. et al. (2005) Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res., 15, 515-522.
10. Lambeck,A.J. et al. (2007) Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: A potential role for interleukin 7. Clin. Cancer Res., 13, 2385-2391.
11. Lokshin,A.E. et al. (2006) Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol. Oncol., 102, 244-251.
12. Lehrer,S. et al. (2004) Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol. Cancer Res. Treat. 3, 411.
13. Pfitzenmaier,J. et al. (2003) Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer, 97, 1211-1216.
14. Ancrile,B. et al. (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev., 21, 1714-1719.
15. Ancrile,B.B. et al. (2008) Oncogenic ras-induced expression of cytokines: A new target of anti-cancer therapeutics. Mol. Interv., 8, 22-27.
16. Trikha,M. et al. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin. Cancer Res., 9, 4653-4665.
17. Liu,J. et al. (2004) A genetically defined model for human ovarian cancer. Cancer Res., 64, 1655-1663.
18. Yang,G. et al. (2006) The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA, 103, 16472-16477.
19. Ahuja,S.K. et al. (1996) CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J. Biol. Chem., 271, 225-232.
20. Allen,S.J. et al. (2007) Chemokine: Receptor structure, interactions, and antagonism. Annu. Rev. Immunol., 25, 787-820.
21. Rossi,D. et al. (2000) The biology of chemokines and their receptors. Annu. Rev. Immunol., 18, 217-242.
22. Coussens,L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
23. Li,A. et al. (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol., 170, 3369-3376.
24. Lim,K.H. et al. (2005) Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell, 8, 381-392.
25. Kendall,S.D. et al. (2005) A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res., 65, 9824-9828.
26. Yeh,E. et al. (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol., 6, 308-318.
27. Linardic,C.M. et al. (2005) Genetic modeling of human rhabdomyosarcoma. Cancer Res., 65, 4490-4495.
28. Hamad,N.M. et al. (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev., 16, 2045-2057.
29. Hahn,W.C. et al. (1999) Creation of human tumour cells with defined genetic elements. Nature, 400, 464-468.
30. O'Hayer,K. et al. (2006) A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. Methods Enzymol., 407, 637-647.
31. Yang,G. et al. (2006) The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA, 103, 16472-16477.
32. Janssens,V. et al. (2001) Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J., 353, 417-439.
33. Sharpless,N.E. et al. (2006) The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov., 5, 741-754.
34. Quintanilla,M. et al. (1986) Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature, 322, 78-80.
35. Cacalano,G. et al. (1994) Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science, 265, 682-684.
36. Wislez,M. et al. (2006) High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res., 66, 4198-4207.
37. Ebrahimi,B. et al. (2004) Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer, 101, 2727-2736.
38. Chin,L. et al. (1999) Essential role for oncogenic Ras in tumour maintenance. Nature, 400, 468-472.
39. Felsher,D.W. (2004) Reversibility of oncogene-induced cancer. Curr. Opin. Genet. Dev., 14, 37-42.
40. Friday,B.B. et al. (2005) K-ras as a target for cancer therapy. Biochim. Biophys. Acta, 1756, 127-144.
41. Adams,G.P. et al. (2005) Monoclonal antibody therapy of cancer. Nat. Biotechnol., 23, 1147-1157.